Neuronetics Prices $30M Offering at $1.60, a Discount to Monday's Close
STIM has more than doubled off its 52-week low of $0.8.
Summary
Neuronetics priced its underwritten offering at $1.60 a share for 18,750,000 shares, raising $30 million gross, and granted the underwriters a 30-day option to purchase up to 2.8 million additional shares at the public offering price per share. That is roughly 9% below the $1.7603 last price, so buyers demanded a discount to take the stock. The raise follows Monday's launch of the offering and an 8-K amending the Perceptive credit agreement, which relaxes revenue covenants only if the company prepays at least $15 million of its $65 million term debt. The new shares are a large addition to the existing share count for a company of this size, and the proceeds go to repaying a portion of outstanding debt and to general corporate purposes rather than growth. The offering is expected to close on or about Nov. 12. The Q3 10-Q already disclosed that Neuronetics expects to miss its March 31, 2027 revenue covenant, which is what put the lender in a position to call the $65 million.
At the time of this announcement, STIM was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $156.2M. The 52-week trading range was $0.80 to $3.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.